Rating Change
Guggenheim analysts initiated coverage on InMed Pharmaceuticals Inc. (NASDAQ:INM) with a rating of Buy on November 09, 2026.
Guggenheim analysts initiated coverage on InMed Pharmaceuticals Inc. (NASDAQ:INM) with a rating of Buy on November 09, 2026.

At publication ·
InMed Pharmaceuticals Inc. (NASDAQ:INM) · new coverage
At a glance
Guggenheim analysts initiated coverage on InMed Pharmaceuticals Inc. (NASDAQ:INM) with a rating of Buy on November 09, 2026.
InMed Pharmaceuticals Inc. operates in the Healthcare sector. The stock currently trades at $15.56 with a market capitalization of $2.5M. The stock has gained 799.4% over the past 52 weeks.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for InMed Pharmaceuticals Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 3 most recent ratings: 3 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 09, 2026 | Guggenheim | Buy | N/A |
| Nov 29, 2021 | HC Wainwright & Co. | Buy | N/A |
| Feb 16, 2021 | Roth Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View INM Stock Page
A rating of Buy from Guggenheim reflects the analyst's outlook on InMed Pharmaceuticals Inc. (NASDAQ:INM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the INM forecast page.
Keep reading
sec_filing ·
sec_filing ·
sec_filing ·
sec_filing ·
Current market data
NASDAQ · INM
$15.56
Up: +$2.35 · +17.79%
Live quote updated